A detailed history of Ubs Oconnor LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 1,549,358 shares of XFOR stock, worth $1.08 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
1,549,358
Holding current value
$1.08 Million
% of portfolio
0.07%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.54 - $0.86 $209,971 - $334,399
388,837 Added 33.51%
1,549,358 $1.04 Million
Q2 2024

Aug 14, 2024

SELL
$0.58 - $1.47 $101,500 - $257,250
-175,000 Reduced 13.1%
1,160,521 $673,000
Q1 2024

May 15, 2024

SELL
$0.72 - $1.46 $293,412 - $594,974
-407,517 Reduced 23.38%
1,335,521 $1.86 Million
Q4 2023

Feb 14, 2024

BUY
$0.61 - $0.99 $111,661 - $181,221
183,052 Added 11.73%
1,743,038 $1.46 Million
Q3 2023

Nov 14, 2023

BUY
$1.03 - $2.02 $1.14 Million - $2.24 Million
1,109,986 Added 246.66%
1,559,986 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$0.82 - $2.49 $369,000 - $1.12 Million
450,000 New
450,000 $873 Million

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $48.1M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.